Last 48 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
BioLife Solutions, Inc.'s quarterly P/E stands at 197.9x. EV/EBITDA has compressed 79.4% YoY to 320.8x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -99.60 | 197.93 | 78.71 | 502.17 | — | — | 24.96 | — | — | — | — | — | — |
| — | — | +215.3% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.64 | 8.54 | 15.65 | 11.07 | 10.13 | 11.24 | — | 9.46 | 12.50 | 11.43 | 10.47 | 6.38 | 6.08 |
| — | -24.0% | — | +17.1% | -19.0% | -1.6% | — | +48.2% | +105.8% | +84.2% | +138.0% | +7.2% | +68.0% | |
| P/B Ratio | 3.26 | 2.52 | 3.16 | 3.51 | 2.97 | 3.05 | 3.57 | 3.55 | 3.07 | 2.53 | 2.16 | 1.81 | — |
| — | -17.3% | -11.5% | -1.1% | -3.3% | +20.8% | +65.7% | +96.0% | — | — | +0.9% | -23.7% | — | |
| P/FCF | 114.37 | — | — | 110.90 | 45.76 | 173.41 | 534.70 | 78.38 | 45.11 | — | 136.91 | — | — |
| — | — | — | +41.5% | +1.4% | — | +290.5% | — | — | — | +139.6% | — | — | |
| EV / EBITDA | — | 320.83 | 40.29 | 247.62 | — | 1561.08 | 95.61 | 386.39 | — | — | — | — | — |
| — | -79.4% | -57.9% | -35.9% | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 8626.74 | 82.61 | — | — | — | 58.58 | — | — | — | — | — | — |
| — | — | +41.0% | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
BioLife Solutions, Inc.'s operating margin was 0.1% in Q1 2026, down 30.9 pp QoQ and up 5.2 pp YoY. The trailing four-quarter average of -8.7% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 4.0% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.6% | 63.3% | 67.5% | 61.4% | 64.6% | 65.9% | -241.6% | 71.3% | 67.0% | 66.4% | 52.1% | 50.9% | 29.9% |
| — | -4.0% | +127.9% | -14.0% | -3.5% | -0.7% | -563.7% | +40.2% | +124.1% | +78.3% | +65.0% | +50.9% | -15.5% | |
| Operating Margin | -12.6% | 0.1% | 31.0% | -0.3% | -65.5% | -5.1% | -40.5% | -5.1% | -18.6% | -17.9% | -42.9% | -37.1% | -38.7% |
| — | +101.9% | +176.5% | +93.8% | -252.6% | +71.5% | +5.5% | +86.3% | +52.0% | +47.7% | -85.7% | -66.9% | -79.8% | |
| Net Margin | -12.6% | 4.3% | 18.8% | 2.2% | -62.3% | -1.9% | -363.9% | -5.6% | -105.1% | -55.4% | -77.0% | -123.6% | -25.8% |
| — | +330.5% | +105.2% | +139.7% | +40.7% | +96.6% | -372.8% | +95.5% | -307.1% | -52.4% | +30.8% | -405.7% | +85.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.4% | 0.3% | 1.0% | 0.2% | -4.5% | -0.1% | 3.7% | -0.5% | -6.3% | -3.0% | -4.0% | -95.2% | — |
| — | +349.6% | -73.6% | +133.7% | +28.5% | +95.8% | +192.4% | +99.4% | — | +88.5% | +68.6% | -3823.5% | — | |
| ROA | -3.0% | 0.3% | 0.9% | 0.2% | -4.0% | -0.1% | 3.2% | -0.5% | -5.3% | -2.5% | -3.2% | -6.9% | -2.3% |
| — | +360.6% | -72.2% | +135.4% | +24.1% | +95.5% | +198.2% | +93.5% | -130.1% | +17.9% | +69.0% | -232.0% | +83.8% | |
| ROIC | -2.8% | 0.0% | 1.2% | -0.0% | -3.8% | -0.3% | 0.3% | -0.3% | -0.8% | -0.7% | -1.6% | -12.0% | — |
| — | +101.8% | +273.7% | +94.4% | -374.4% | +57.3% | +120.9% | +97.1% | — | +94.4% | +15.0% | -646.3% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
BioLife Solutions, Inc.'s Debt/EBITDA ratio is 20.5x, up from 2.5x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 54.3% YoY to 7.30x, strengthening the short-term liquidity position. Debt/Equity has declined for 7 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.09 | 0.12 | 0.11 | 0.12 | 0.10 | 0.13 | — |
| — | -47.8% | -44.4% | -51.6% | -38.7% | -37.8% | -13.7% | -9.4% | — | — | -16.5% | +16.2% | — | |
| Debt / EBITDA | — | 20.46 | 2.48 | 16.59 | — | 162.34 | 9.77 | 51.80 | — | — | — | — | — |
| — | -87.4% | -74.6% | -68.0% | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.94 | 7.30 | 5.23 | 4.66 | 4.43 | 4.73 | 4.54 | 2.78 | 2.86 | 2.89 | 2.86 | 2.74 | 3.04 |
| — | +54.3% | +15.1% | +67.8% | +54.8% | +63.7% | +58.9% | +1.4% | -5.8% | +3.0% | -7.9% | -25.5% | -14.3% | |
| Quick Ratio | 4.63 | 5.50 | 3.92 | 3.64 | 3.45 | 3.74 | 3.66 | 1.78 | 1.81 | 1.77 | 1.83 | 1.72 | 2.05 |
| — | +47.2% | +7.1% | +104.5% | +91.0% | +111.5% | +100.0% | +3.2% | -11.8% | -8.6% | -21.2% | -37.6% | -19.4% | |
| Interest Coverage | -3.46 | — | 23.12 | -0.18 | — | — | 43.47 | -5.48 | -3.62 | -14.70 | -25.48 | -59.96 | -13.25 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BLFS stock.
BioLife Solutions, Inc.'s current P/E is -99.6x. The average P/E over the last 3 quarters is 259.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioLife Solutions, Inc.'s current operating margin is -12.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioLife Solutions, Inc.'s business trajectory between earnings reports.